Combination of Waist Circumference and Circulating Levels of IGFBP-2 As a Simple Screening Tool for Early Detection of Metabolic Dysfunction-Associated Steatotic Liver Disease

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2024 Sep 10

PMID 39252871

Authors

Chloe Rauzier

Dominic J Chartrand

Natalie Almeras

Isabelle Lemieux

Eric Larose

Patrick Mathieu

Philippe Pibarot

Benoit Lamarche

Caroline Rheaume

Paul Poirier

Jean-Pierre Despres

Frederic Picard

Affiliations

Soon will be listed here.

Abstract

Optimal non-invasive biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD) remain elusive, especially in the detection of early stages. This study tested in an asymptomatic cohort of 171 men (49.2 ± 8.6 years) and 131 women (51.8 ± 8.5 years) whether waist circumference (WC) and circulating levels of insulin-like growth factor-binding protein 2 (IGFBP-2) could identify individuals with liver fat >5% as assessed by magnetic resonance spectroscopy. Participants with high WC (> 85 or 90 cm for women and men, respectively) and low IGFBP-2 (< 260 or 230 ng/mL for women and men, respectively) were characterized by a higher risk of having MASLD (46.3%, < 0.0001). Among the 68 individuals with MASLD, 73.5% fell into the subgroup with high WC and low IGFBP-2 concentrations ( < 0.0001). When combined, these markers reached a sensitivity of 73.5% and specificity of 75.2% for MASLD. Thus, WC and plasma IGFBP-2 levels might be useful as a novel, simple, and non-invasive index to support existing tools in the identification of individuals at risk of early-stage MASLD.

References

Bao Y, Lu J, Wang C, Yang M, Li H, Zhang X . Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis. 2008; 201(2):378-84. DOI: 10.1016/j.atherosclerosis.2008.03.001. View

Carter S, Li Z, Lemieux I, Almeras N, Tremblay A, Bergeron J . Circulating IGFBP-2 levels are incrementally linked to correlates of the metabolic syndrome and independently associated with VLDL triglycerides. Atherosclerosis. 2014; 237(2):645-51. DOI: 10.1016/j.atherosclerosis.2014.09.022. View

Sanyal A, Shankar S, Calle R, Samir A, Sirlin C, Sherlock S . Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. Nat Med. 2022; 28(3):430-432. PMC: 9588405. DOI: 10.1038/s41591-021-01652-8. View

Boughanem H, Yubero-Serrano E, Lopez-Miranda J, Tinahones F, Macias-Gonzalez M . Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance. Int J Mol Sci. 2021; 22(3). PMC: 7865532. DOI: 10.3390/ijms22031133. View

Chen X, Tang Y, Chen S, Ling W, Wang Q . IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study. Endocr Connect. 2021; 10(10):1315-1325. PMC: 8562889. DOI: 10.1530/EC-21-0353. View

Albhaisi S, Chowdhury A, Sanyal A . Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2020; 1(4):329-341. PMC: 7001558. DOI: 10.1016/j.jhepr.2019.08.002. View

Newton K, Lavine J, Wilson L, Behling C, Vos M, Molleston J . Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis. Hepatology. 2020; 73(3):937-951. PMC: 7669708. DOI: 10.1002/hep.31317. View

Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N . Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation. 2000; 102(2):179-84. DOI: 10.1161/01.cir.102.2.179. View

Rauzier C, Chartrand D, Almeras N, Lemieux I, Larose E, Mathieu P . Associations of insulin-like growth factor binding protein-2 with metabolic profile and hepatic fat deposition in asymptomatic men and women. Am J Physiol Endocrinol Metab. 2023; 325(1):E99-E105. DOI: 10.1152/ajpendo.00108.2023. View

10.

Blackburn P, Lemieux I, Lamarche B, Bergeron J, Perron P, Tremblay G . Type 2 diabetes without the atherogenic metabolic triad does not predict angiographically assessed coronary artery disease in women. Diabetes Care. 2007; 31(1):170-2. DOI: 10.2337/dc07-0272. View

11.

Chartrand D, Larose E, Poirier P, Mathieu P, Almeras N, Pibarot P . Visceral adiposity and liver fat as mediators of the association between cardiorespiratory fitness and plasma glucose-insulin homeostasis. Am J Physiol Endocrinol Metab. 2020; 319(3):E548-E556. DOI: 10.1152/ajpendo.00251.2020. View

12.

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

13.

Dong J, Yu J, Li Z, Gao S, Wang H, Yang S . Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting. J Cachexia Sarcopenia Muscle. 2021; 12(3):704-716. PMC: 8200427. DOI: 10.1002/jcsm.12692. View

14.

Tejani S, McCoy C, Ayers C, Powell-Wiley T, Despres J, Linge J . Cardiometabolic Health Outcomes Associated With Discordant Visceral and Liver Fat Phenotypes: Insights From the Dallas Heart Study and UK Biobank. Mayo Clin Proc. 2021; 97(2):225-237. PMC: 8818017. DOI: 10.1016/j.mayocp.2021.08.021. View

15.

Kratzsch J, Blum W, Schenker E, Keller E . Regulation of growth hormone (GH), insulin-like growth factor (IGF)I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Diabetes. 1995; 103(5):285-91. DOI: 10.1055/s-0029-1211366. View

16.

Stanley T, Fourman L, Zheng I, McClure C, Feldpausch M, Torriani M . Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2020; 106(2):e520-e533. PMC: 7823253. DOI: 10.1210/clinem/dgaa792. View

17.

Salgado A, de Carvalho L, Oliveira A, Santos V, Vieira J, Parise E . Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010; 47(2):165-9. DOI: 10.1590/s0004-28032010000200009. View

18.

Fahlbusch P, Knebel B, Horbelt T, Barbosa D, Nikolic A, Jacob S . Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men. Int J Mol Sci. 2020; 21(11). PMC: 7312731. DOI: 10.3390/ijms21114144. View

19.

Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson L . Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137(3):865-72. DOI: 10.1053/j.gastro.2009.06.005. View

20.

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View